Prevention of Atopy and Allergic Disease: Type of Infant Formula

2006 ◽  
pp. 109-123
Author(s):  
Hugh A. Sampson
Keyword(s):  
Infant Formula ◽  
Allergic Disease ◽  
Disease Type

scholarly journals The Role of Hydrolyzed Formula in Allergy Prevention

2017 ◽  
Vol 70 (Suppl. 2) ◽  
pp. 38-45 ◽  
Author(s):  
Michael D. Cabana
Keyword(s):  
Allergic Rhinitis ◽  
Food Allergy ◽  
Infant Formula ◽  
Allergic Disease ◽  
Clinical Studies ◽  
Atopic Disease ◽  
Allergy Prevention ◽  
Preventive Effect ◽  
History Of ◽  
Hydrolyzed Formula

Asthma, eczema, food allergy, and allergic rhinitis are some of the most common pediatric, chronic conditions in the world. Breastfeeding is the optimal way to feed all infants. For those infants who are exposed to infant formula, some studies suggest that certain partially hydrolyzed or extensively hydrolyzed formulas may decrease the risk of allergic disease compared to nonhydrolyzed formulas for children with a family history of atopic disease. Overall, there is some evidence to suggest that partially hydrolyzed whey formulas and extensively hydrolyzed casein formulas may decrease the risk of developing eczema for infants at high risk of allergic disease. The evidence for a preventive effect of hydrolyzed formulas on allergic rhinitis, food allergy, and asthma is inconsistent and insufficient. Finally, the qualitative changes to the peptides by the method of hydrolysis, not just the degree of protein hydrolysis, may have a large influence on the preventive effect of a particular infant formula for the potential risk of allergic disease. As a result, it may be difficult to generalize findings from clinical studies using a specific infant formula to other infant formulas from different manufacturers using different methods of hydrolysis. Further clinical studies are needed to help clinicians identify which infants may benefit from early intervention, as well as which specific hydrolyzed formulas are best suited to decrease the risk of future allergic disease.

Effect of a partially hydrolyzed whey infant formula at weaning on risk of allergic disease in high-risk children: A randomized controlled trial

2011 ◽  
Vol 128 (2) ◽  
pp. 360-365.e4 ◽  
Author(s):  
Adrian J. Lowe ◽  
Clifford S. Hosking ◽  
Catherine M. Bennett ◽  
Katrina J. Allen ◽  
Christine Axelrad ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
High Risk ◽  
Infant Formula ◽  
Allergic Disease ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
High Risk Children

scholarly journals Partially Hydrolyzed Whey Protein: A Review of Current Evidence, Implementation, and Further Directions

2021 ◽  
Vol 5 (1) ◽  
pp. 53
Author(s):  
Badriul Hegar ◽  
Zakiudin Munasir ◽  
Ahmad Suryawan ◽  
I gusti Lanang Sidhiarta ◽  
Ketut Dewi Kumara Wati ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Infant Formula ◽  
Allergic Disease ◽  
Intact Protein ◽  
Current Evidence ◽  
Cow’S Milk ◽  
Cow's Milk ◽  
Breastfed Infants ◽  
Functional Gi Disorders

Background: Human milk is known to be the best nutrition for infants as it provides many health benefits. For non-breastfed infants, cow's milk based infant formula is the most optimal option to provide the needed nutrition. However, approximately 2-5% of all formula-fed infants experience cow’s milk allergy during their first year of life. Partially hydrolyzed whey formula (pHF-W) have been widely recommended to prevent the development of allergic disease in infants. However, according to epidemiological data, approximately half of the infants developing allergy are not part of the at-risk group.Objectives and Methods: This article aims to review the effects of pHF-W in preventing allergy, especially atopic disease, in all non-breastfed infants, as well as the safety aspect of pHF-W if used as routine formula. The role of pHF-W in the management of functional gastro-intestinal (GI) disorders is also reviewed.Results: Several clinical studies showed that pHF-W decrease the number of infants with eczema. The strongest evidence is provided by the 15-year follow up of the German Infant Nutritional Intervention study which showed reduction in the cumulative incidence of eczema and allergic rhinitis in pHF-W (OR 0.75, 95% CI 0.59-0.96 for eczema; OR 0.67, 95% CI 0.47-0.95 for allergic rhinitis) and casein extensively hydrolysed formula  group (OR 0.60, 95% CI 0.46-0.77 for eczema; OR 0.59, 95% CI 0.41-0.84 for allergic rhinitis), compared to CMF as a control, after 15 years of follow-up. pHF-W was also found to be beneficial in the management of functional GI disorders such as regurgitation, constipation and colic.Conclusions: The use of pHF-W in allergic infants has been recommended in various guidelines across the countries, as a primary prevention of allergic disease. One pHF-W has been approved by the US FDA and the European Commission's European Food Safety Authority (EFSA) for its safety and suitability as a routine infant formula for all healthy infants. According to the data obtained in the management of functional GI disorders, pHF-W is better tolerated than formula with intact protein. Further studies assessing the effect of routine use of pHF-W in a larger population of non-breastfed infants should also be conducted, in order to observe any potential harm and to determine the benefit and cost-effectiveness ratio.

Refractory coeliac disease type I and II; Pilot-treatment with azathioprine and predinison

2001 ◽  
Vol 120 (5) ◽  
pp. A131-A131 ◽  
Author(s):  
C MULDER ◽  
P WAHAB ◽  
A TAN ◽  
J MEIJER
Keyword(s):  
Coeliac Disease ◽  
Disease Type ◽  
Type I ◽  
Refractory Coeliac Disease
Sign in / Sign up

Export Citation Format

Share Document